Evidence map›Paper›PMID 35186756›Full record

ReviewFrontiers in oncology2022

Potential Biomarkers for Liver Cancer Diagnosis Based on Multi-Omics Strategy.

Fanghua Chen, Junming Wang, Yingcheng Wu, Qiang Gao, Shu Zhang

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 2 pooled it
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 41 citations in OpenAlex.

  1. Diagnostic accuracy of methylatedFrontiers in endocrinology · 2025
    Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Review
  7. Illuminating diabetesWorld journal of diabetes · 2025
    Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Biomarker in Hepatocellular Carcinoma.Indian journal of surgical oncology · 2024
    Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Fanghua ChenCenter for Tumor Diagnosis & Therapy, Jinshan Hospital, Fudan University, Shanghai, China.
Junming WangLiver Cancer Institute, Zhongshan Hospital, and Key Laboratory of Carcinogenesis and Cancer Invasion (Ministry of Education), Fudan University, Shanghai, China.
Yingcheng WuLiver Cancer Institute, Zhongshan Hospital, and Key Laboratory of Carcinogenesis and Cancer Invasion (Ministry of Education), Fudan University, Shanghai, China.
Qiang GaoCenter for Tumor Diagnosis & Therapy, Jinshan Hospital, Fudan University, Shanghai, China.
Shu ZhangCenter for Tumor Diagnosis & Therapy, Jinshan Hospital, Fudan University, Shanghai, China.
Fudan University · CNJinshan Hospital of Fudan University · CNZhongshan Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liver cancer is the fourth leading cause of cancer-related death worldwide. Hepatocellular carcinoma (HCC) accounts for about 85%-90% of all primary liver malignancies. However, only 20-30% of HCC patients are eligible for curative therapy mainly due to the lack of early-detection strategies, highlighting the significance of reliable and accurate biomarkers. The integration of multi-omics became an important tool for biomarker screening and unique alterations in tumor-associated genes, transcripts, proteins, post-translational modifications and metabolites have been observed. We here summarized the novel biomarkers for HCC diagnosis based on multi-omics technology as well as the clinical significance of these potential biomarkers in the early detection of HCC.

Indexed as

biomarkerclinical diagnosisearly detectionhepatocellular carcinomamulti-omics

Identifiers

PMID35186756
PMCPMC8851237
OpenAlexW4213033144

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.